Agios Pharmaceuticals, Inc. (AGIO): Net Income
-$412.78M
Year ended 2025-12-31
-$411.29M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$412.78M | n/m | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $673.73M | n/m | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | -$352.09M | n/m | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | -$231.80M | n/m | 2025-02-13, From 2022-01-01 |
| 2021-12-31 | $1.60B | n/m | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | -$327.37M | n/m | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | -$411.47M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$346.03M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$314.67M | n/m | 2020-02-19, From 2017-01-01 |
| 2016-12-31 | -$198.47M | n/m | 2019-02-14, From 2016-01-01 |
| 2015-12-31 | -$117.73M | n/m | 2018-02-14, From 2015-01-01 |
| 2014-12-31 | -$53.50M | n/m | 2017-02-16, From 2014-01-01 |
| 2013-12-31 | -$39.41M | n/m | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | -$20.10M | n/m | 2015-02-24, From 2012-01-01 |
| 2011-12-31 | -$23.71M | n/a | 2014-03-18, From 2011-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | -$412.78M | n/m |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $29.82M | n/m |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $808.0K | +621.4% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | -$164.08M | n/m |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | -$265.94M | n/m |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | -$14.25M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$50.34M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$170.37M | n/m |
| Journey Medical Corp (DERM) | 2025-12-31 | -$11.43M | n/m |
Compare AGIO, QTTB, INBP, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗